Clinical trials: Polycystic Kidney Disease
Adult Polycystic Kidney Disease, Kidney Neoplasms
Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function
The number of people with kidney disease is constantly rising and renal failure represents one of the major health care burdens globally.
- Conditions
- Adult Polycystic Kidney Disease, Kidney Neoplasms, Kidney Dysfunction
- Trial name
- NCT03442647
- Testing
- sinistrin clearance dynamic measurement
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Thomas Mueller
Autosomal Dominant Polycystic Kidney
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
Investigator initiated controlled multi-centre trial in a Prospective, Randomised, Open, Blinded Endpoint (PROBE) design. Patients will be randomised in a 1:1 ratio either to treatment with tolvaptan for six weeks followed by six…
- Trial name
- PoCKET (NCT03596957)
- Testing
- Tolvaptan
- Where
- 6 sites in Denmark
- Volunteers
- 90 people
- Sponsor
- Lisbet Brandi
Autosomal Dominant Polycystic Kidney Disease
ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure?
Autosomal dominant polycystic kidney disease (ADPKD) is first genetic kidney disease and fourth etiology of end stage renal disease in the world. Peritoneal dialysis is underuse in this population.
- Trial name
- PDP-ADPKD (NCT03970018)
- Testing
- Intra-peritoneal pressure
- Where
- France
- Volunteers
- 210 people
- Sponsor
- CHU de Reims
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
This is a Phase 1, First-in-Human study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of PYC-003 in healthy adult participants and adult participants with confirmed PKD1…
- Trial name
- NCT06714006
- Testing
- PYC-003
- Where
- 12 sites in Australia, Hong Kong and 1 more
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- PYC Therapeutics
Autosomal Dominant Polycystic Kidney Disease
Repository Study of Autosomal Dominant Polycystic Kidney Disease
The design and establishment of the Polycystic Kidney Disease (PKD) Data Repository does not require, and may be constrained by, a narrowly conceived hypothesis.
- Trial name
- Repository (NCT01988038)
- Where
- United States
- Sponsor
- The Rogosin Institute
Chronic Kidney Disease, Nephrolithiasis
Kidney Sodium Functional Imaging
The corticomedullary gradient is largely responsible for developing the gradients that are needed to concentrate urine (more solutes and less water).
- Conditions
- Chronic Kidney Disease, Nephrolithiasis, ADPKD
- Trial name
- NCT05014178
- Testing
- Sodium-23 MRI
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Autosomal Dominant Polycystic Kidney Disease
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
The purpose of this study is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of…
- Trial name
- HCY (NCT05193981)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Polycystic Kidney Disease
Well-Formulated Ketogenic Diet Polycystic Kidney Disease
This is a prospective study to determine ketogenic diet effect on htTKV, GFR, microalbuminuria. This is a single-center study of 20 patients with ADPKD and deemed high risk for progression to ESRD.
- Trial name
- NCT06325644
- Testing
- Ketogenic Diet, Ketone/Glucose Monitoring, CGM/CKM
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ohio State University
Peritoneal Dialysis, Polycystic Kidney Diseases
The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney Disease
Background: Polycystic kidney disease (PKD) is the most common hereditary kidney disease. Peritoneal dialysis (PD) in such patients is restricted because the significantly enlarged kidneys and liver may lead to the increase of…
- Trial name
- NCT06841224
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of renal failure. For several decades, ADPKD was regarded as an adult-onset disease.
- Trial name
- ADPKD (NCT04338048)
- Where
- 4 sites in United States
- Volunteers
- 300 people
- Sponsor
- Children's Hospital of Philadelphia
Kidney, Polycystic, Autosomal Dominant
High Water Intake to Slow Progression of Polycystic Kidney Disease
Polycystic kidney disease (PKD) is a genetic disease that occurs in 1 in 500 individuals and leads to kidney failure in half of all affected. Currently, no treatments exist for PKD.
- Trial name
- NCT00784030
- Testing
- Water
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Polycystic Kidney Disease
Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)
The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.
- Trial name
- NCT02558595
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Kansas Medical Center
ADPKD
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function.
- Trial name
- HYDRO-PROTECT (NCT05373264)
- Testing
- Hydrochlorothiazide 25 mg
- Where
- 25 sites in Austria, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- University Medical Center Groningen
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
- Trial name
- NCT04786574
- Testing
- Tolvaptan (OPC-41061)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autosomal Dominant Polycystic Kidney
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
- Trial name
- EMPA-PKD (NCT06391450)
- Testing
- Empagliflozin 10 MG
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Hannover Medical School
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited cystic disorder characterised by the progressive degeneration of the renal parenchyma into cystic formations, with involvement of other organs to varying…
- Trial name
- NCT07535385
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Autosomal Dominant Polycystic Kidney Disease, Glomerular Filtration Rate > 40 ml/Min
Effects of Somatostatin on ADPKD Heart
Autosomal dominant polycystic kidney disease (ADPKD) is associated with early onset hypertension and left ventricular (LV) hypertrophy.
- Trial name
- NCT02119013
- Testing
- Octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy…
- Trial name
- NCT07788014
- Testing
- GV-100
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gilva Therapeutics Inc.
Chronic Kidney Diseases, Alport Syndrome
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with…
- Conditions
- Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
- Trial name
- EAGLE (NCT03749447)
- Testing
- Bardoxolone methyl
- Where
- 87 sites in United States, Australia and 4 more
- Volunteers
- 270 people
- Sponsor
- Biogen
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Robotic vs Open Nephrectomy for ADPKD
The goal of this observational prospective cohort study is to evaluate the feasibility, safety, and postoperative outcomes of robotic-assisted unilateral native nephrectomy using the Medtronic Hugo™ RAS system compared with the…
- Trial name
- ADPKDR-O (NCT07355114)
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- University of Bologna